A melanocortin-receptor agonist derived from Melanotan II research, FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Notable as one of the only peptides in this category with a formal drug approval.
Sexual health
A non-selective melanocortin-receptor agonist originally studied for skin tanning and erectile dysfunction, whose sexual-desire side effects led directly to the development of the FDA-approved drug bremelanotide (PT-141). Widely sold gray-market for tanning despite no approval for that use.
Sexual health
The synthetic form of the body's own gonadotropin-releasing hormone, historically FDA-approved for pituitary function testing and pulsatile ovulation induction. Now widely discussed off-label alongside testosterone replacement therapy to help preserve natural testicular function and fertility.
Sexual health
A naturally occurring neuropeptide that is the master regulator of the reproductive hormone axis, now in early clinical development as a fertility and psychosexual therapeutic. Distinct from the melanocortin-based sexual-health peptides: it works directly on the reproductive hormone cascade.
Sexual health